An update on non-peptide angiotensin receptor antagonists and related RAAS modulators

Life Sciences

Volumn 81, Issue 8, 2007, Pages 615-639

  Aulakh, G K ^a   Sodhi, R K ^a   Singh, M ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Agonists; Angiotensin; Antagonists; AT1; AT2

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 [[5 ETHYL 3 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 1,3,4 THIADIAZOLIN 2 YLIDENE]CARBAMOYL] 1 CYCLOPENTENECARBOXYLIC ACID; 2 BUTYL 1 (4 CARBOXYBENZYL) 4 CHLORO 5 IMIDAZOLEACETIC ACID; 2 BUTYL 1 [4 (2 CARBOXYBENZAMIDO)BENZYL] 4 CHLORO 5 IMIDAZOLEACETIC ACID METHYL ESTER; 2 BUTYL 1 [4 (6 CARBOXY 2,5 DICHLOROBENZOYLAMINO)BENZYL] 6 [N (METHYLAMINOCARBONYL) N PENTYLAMINO]BENZIMIDAZOLE; 2 BUTYL 4 CHLORO 1 (2 CHLOROBENZYL) 5 IMIDAZOLEACETIC ACID; 2 BUTYL 4 CHLORO 1 (2 NITROBENZYL) 5 IMIDAZOLEACETIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; 4 [5 (2 BENZOYLBENZYLOXYCARBONYL) 4 ETHYL 2 PROPYL 1 IMIDAZOLYLMETHYL] 3 FLUORO 2' ISOPENTYLOXYCARBONYLAMINOSULFONYLBIPHENYL; 4' (2 BUTYL 4 CHLORO 5 HYDROXYMETHYL 1H IMIDAZOL 1 YLMETHYL) 2 BIPHENYLCARBOXYLIC ACID; 4,5,6,7 TETRAHYDRO 8 OXO 2 PROPYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL]CYCLOHEPTIMIDAZOLE; 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1 (4 METHOXY 3 METHYLBENZYL) 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BAY 106735; BIBS 39; BMS 1; BMS 3; CANDESARTAN; CANDESARTAN HEXETIL; CGS 35601; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EK 112; EMBUSARTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; EPROSARTAN; EXP 801; GW 660511X; IMIDAZOLE DERIVATIVE; IRBESARTAN; L 159686; L 159689; L 161638; L 162132; L 162620; L 163017; L 163579; L 163958; LOSARTAN; LOSARTAN POTASSIUM; MEMBRANE METALLOENDOPEPTIDASE; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; OLMESARTAN; PD 126055; RENIN; RENIN INHIBITOR; SAPRISARTAN; SPP 1100; SPP 1148; SPP 600; SPP 635; SPP 800; SUN C8257; TASOSARTAN; TEI E548; TELMISARTAN; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; XR 510; Z 13752A; ZOLASARTAN;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; ELECTROLYTE BALANCE; FLUID BALANCE; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ACRYLATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; PROTEASE INHIBITORS; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; RENIN; RENIN-ANGIOTENSIN SYSTEM; THIOPHENES;

EID: 34547972711     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.06.007     Document Type: Review

References (238)

1. Abdi R., Dong V.M., Lee C.J., and Ntoso K.A. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 22 9 (2002) 1173-1175
2. 2 receptor expression and signaling. Physiological Genomics 2 (2000) 13-20
3. Alwan S., Polifka J.E., and Friedman J.M. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Research and Clinical Molecular Teratology 73 2 (2005) 123-130
4. 1-receptor antagonist in stroke-prone spontaneously hypertensive rats. Japanese Journal of Pharmacology 69 (1995) 215-222
5. Anand K., Mooss A.N., Hee T.T., and Mohiuddin S.M. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. American Heart Journal 152 2 (2006) 217-222
6. Athyros V.G., Mikhailidis D.P., Kakafika A.I., Tziomalos K., and Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opinion in Pharmacotherapy 8 5 (2007) 529-535
7. Bali A., Bansal Y., Sugumaran M., Saggu J.S., Balakumar P., Kaur G., Bansal G., Sharma A., and Singh M. Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists. Bioorganic & Medicinal Chemistry Letters 15 (2004) 3962-3965
8. 2 receptor stimulation enhances antihypertensive effect of AT1 receptor antagonist in hypertensive rats. Hypertension 34 (1999) 1112-1116
9. Basso N., Paglia N., Stella I., de Cavanagh E.M., Ferder L., del Rosario L.A.M., and Inserra F. Protective effect of the inhibition of the renin-angiotensin system on aging. Regulatory Peptides 128 3 (2005) 247-252
10. Bernal J., Pitta S.R., and Thatai D. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. American Journal of Cardiovascular Drugs 6 6 (2006) 373-381
11. Blankestijn P.J. Effects of eprosartan in chronic kidneydisease. Journal of Clinical and Basic Cardiology 8 (2005) 15-17
12. 2 sub-type. Journal of Medicinal Chemistry 34 (1991) 3248-3260
13. Brady A.J. Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials. Clinical Drug Investigation 27 3 (2007) 149-161
14. Breithaupt-Grogler K., Malerczyk C., and Belz G.G. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist-characterization by use of Schild regression technique in man. International Journal of Clinical Pharmacology and Therapeutics 35 (1997) 434-441
15. Brooks D.P., Ohlstein E.H., and Ruffolo Jr. R.R. Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypothesis from clinical data. American Heart Journal 138 (1999) 246-251
16. Brosnihan K.B. Effect of the angiotensin-(1-7) peptide on nitric oxide release. American Journal of Cardiology 82 (1998) 17S-19S
17. Brunner H.R. Olmesartan medoxomil: current status of its use in monotherapy. Vascular Health Risk Management 2 4 (2006) 327-340
18. Buhlmayer P., Furet P., Criscione L., de Gasparo M., Whitebread S., Schmidlin T., Lattmann R., and Wood J. Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series. Bioorganic & Medicinal Chemistry Letters 4 (1994) 29-34
19. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 103 (2001) 904-912
20. 1 receptor antagonists: clinical development and future. Therapie 53 (1998) 279-284
21. Burnier M., and Brunner H.R. Angiotensin II receptor antagonists. Lancet 355 (2000) 637-645
22. Cao Z., Dean R., Wu L., Casley D., and Cooper M.E. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension 34 (1999) 408-414
23. Case D.B., Wallace J.M., and Laragh J.H. Comparison between saralasin and converting enzyme inhibitor in hypertensive diseases. Kidney International 15 (1979) S107-S114
24. Chang R.S.L., Siegl P.K.S., Clineschmidt B.V., Mantlo N.B., Chakravarty P.K., Greenlee W.J., Patchett A.A., and Lotti V.J. In vitro pharmacology of L-158809, a new highly potent and selective angiotensin II receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 262 (1992) 133-138
25. 2 receptors. European Journal of Pharmacology 294 (1995) 429-437
26. Chappell M.C., Tallant E.A., Diz D.I., and Ferrario C.M. The renin-angiotensin system and cardiovascular homeostasis. In: Husain A., and Graham R. (Eds). Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery (2000), Harwood Academic Publishers, Amsterdam 3-22
27. Chiu A.T., Carini D.J., Johnson A.L., Mc Call D.E., Price Jr. W.A., Thoolen M.J.M.C., Wong P.C., Taber R.L., and Timmermans P.B.M.W.M. Nonpeptide angiotensin II (AII) receptor antagonists. II. Pharmacology of S-8308. European Journal of Pharmacology 157 (1988) 13-21
28. Chiu A.T., Carini D.J., Duncia J.V., Leung K.H., Mc Call D.E., Price Jr. W.A., Wong P.C., Smith R.D., Wexler R.R., and Timmermans P.B.M.W.M. DuP 532: a second generation of nonpeptide angiotensin II receptor antagonists. Biochemical and Biophysical Research Communications 177 (1991) 209-217
29. Chiu A.G., Krowiak E.J., and Deeb Z.E. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 111 10 (2001) 1729-1731
30. Christophe B., Libon R., Cazaubon C., Nisato D., Manning A., and Chatelain P. Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in pithed rat-Potential mechanisms of action. European Journal of Pharmacology 281 (1995) 161-171
31. Chung, O., Unger, T., 1999. Angiotensin II receptor blockade and end organ protection. American Journal of Hypertension 12(12) (1-2), 150S.
32. 2 receptors. Blood Pressure 5 2 (1996) 47-52
33. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 345 23 (2001) 1667-1675
34. Coppey L.J., Davidson E.P., Rinehart T.W., Gellett J.S., Oltman C.L., Lund D.D., and Yorek M.A. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 55 2 (2006) 341-348
35. Csajka C., Buclin T., Brunner H.R., and Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clinical Pharmacokinetics 32 (1997) 1-29
36. Dahlof B., Devereuse R., De Faire U., and for the LIFE study group. The losartan intervention for endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. American Journal of Hypertension 10 (1997) 705-713
37. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedderson O., Lindholm L.H., Nieminen N.H., Omvik P., Oparil S., Wedel H., and and for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 995-1003
38. Danser A.H.J., and Deinum J. Renin, Prorenin and the putative (Pro)renin receptor. Hypertension 46 (2005) 1069-1076
39. Daull P., Benrezzak O., Arsenault D., Pheng L.H., Blouin A., Cayer J., Beaudoin M., Belleville K., Sirois P., Nantel F., Jeng A.Y., and Battistini B. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained,and spontaneously hypertensive rats. American Journal of Hypertension 18 12 Pt1 (2005) 1606-1613
40. Daull P., Blouin A., Belleville K., Beaudoin M., Arsenault D., Leonard H., Sirois P., Nantel F., Jeng A.Y., and Battistini B. Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats. Experimental Biology and Medicine (Maywood) 231 6 (2006) 830-833
41. de Gasparo M., Husain A., Alexander W., Catt K.J., Chiu A.T., Drew M., Goodfriend T., Harding J.W., Inagami T., and Timmermans P.B.M.W.M. Proposed update of angiotensin receptor nomenclature. Hypertension 25 (1995) 924-939
42. de Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International Union of Pharamacology. XXIII. The angiotensin II receptors. Pharmacological Reviews 52 (2000) 415-472
43. de Ligt R.A., Kourounakis A.P., and IJzerman A.P. Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. British Journal of Pharmacology 130 (2000) 1-12
44. de Moura M., Sousa dos Santos R.A., and Fontes M.A.P. Evidence for a functional cardiac interaction between losartan and angiotensin-(1-7) receptors revealed by orthostatic tilting test in rats. British Journal of Pharmacology 144 (2005) 755-760
45. Devereux R.B., and Dahlof B. Potential mechanisms of stroke benefit favoring losartan in the losartan intervention for endpoint reduction in hypertension (LIFE) study. Current Medical Research Opinions 23 2 (2007) 443-457
46. Dickstein K., Kjekshus J., and OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360 9335 (2002) 752-760
47. Dickstein K., Kjekshus J., and for the OPTIMAAL study group. Comparison of the effects of losartan and captopril on mortality in patients following acute myocardial infarction: the OPTIMAAL trial design. optimal therapy in myocardial infarction with the angiotensin II antagonist losartan. American Journal of Cardiology 83 (1999) 477-481
48. Doggrell S.A. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Expert Opinion on Pharmacotherapy 4 7 (2003) 1185-1188
49. Doggrell S.A., and Wanstall J.C. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Canadian Journal of Physiology and Pharmacology 83 2 (2005) 123-130
50. Dowle M.D., Judd D.B., Middlemiss D., Scopes D.I.C., Ross B.C., Pass M., Tranquillini E., Jack T.I., Hobson J.E., Panchal T.A., Stuart P.G., Drew G.M., Robertson M.J., Hilditch A., Clark K.L., Travers A., Hunt A.A.E., Manchee G.R., Walker D.G., Eddershaw P.J., Donnelly M.D., and Bayliss M.K. Benzofuran based angiotensin II antagonists related to GR 117289. Part III. GR 138950, a triflamide with high oral bioavailability. Bioorganic & Medicinal Chemistry Letters 3 (1993) 2047-2050
51. Dudley D.T., Panek R.L., Major T.C., Lu G.H., Bruns R.F., Klinkefus B.A., Hodges J.C., and Weishaar R.E. Subclasses of angiotensin II binding sites and their functional significance. Molecular Pharmacology 80 (1990) 370-377
52. Duncia J.V., Chiu A.T., Carini D.J., Gregory G.B., Johnson A.L., Price Jr. W.A., Wells G.J., Wong P.C., Calabrese J.C., and Timmermans P.B.M.W.M. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. Journal of Medicinal Chemistry 33 (1990) 1312-1329
53. + expression in rat aortic vascular smooth muscle cells in vitro. Journal of Pharmacology and Experimental Therapeutics 280 (1997) 447-453
54. Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contributions in Nephrology 151 (2006) 122-134
55. Edwards R.M., Aiyar N., Ohlstein E.H., Weidley E.F., Giffin E., Ezekiel M., Keenan R.M., Ruffolo Jr. R.R., and Weinstock J. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist: SK&F 108566. Journal of Pharmacology and Experimental Therapeutics 260 (1992) 175-181
56. Elokdah H.M., Friedrichs G.S., Chai S.Y., Harrison B.L., Primeau J., Chlenov M., and Crandall D.L. Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects. Bioorganic & Medicinal Chemistry Letters 12 15 (2002) 1967-1971
57. Ferrari P. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Nephrology (Carlton) 12 1 (2007) 81-89
58. Fisher J.F., Harrison A.W., Bundy G.L., Wilkinson K.F., and Rush B.D. Peptide to glycopeptide glycosylated oligopeptide renin inhibitors with attenuated in vivo clearance properties. Journal of Medicinal Chemistry 34 (1991) 3140-3143
59. Flesch M., Ko Y., and Seul C. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells. European Journal of Pharmacology 289 (1995) 399-402
60. Frohlich E.D. Renin-angiotensin system inhibition improves coronary flow reserve in hypertension. Journal of Cardiovascular Pharmacology 37 1 (2001) S35-S39
61. Furukawa Y., Kishimoto S., and Nishikawa K. Hypotensive imidazole derivatives. U.S. Patent 4,340,598 (1982), Issued to Takeda Chemical Industries, Ltd., Osaka, Japan
62. Furukawa, Y., Kishimoto, S., Nishikawa, K., 1982b. Hypotensive imidazole -5- acetic acid derivatives. U.S. Patent 4,355,040. Issued to Takeda Chemical Industries Ltd., Osaka, Japan.
63. Garcha R.S., Server P.S., and Hughes A.D. Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries. British Journal of Pharmacology 127 (1999) 1876-1882
64. Gard P.R., and Rusted J.M. Angiotensin and Alzheimer's disease: therapeutic prospects. Expert Reviews in Neurotherapy 4 1 (2004) 87-96
65. Gavras H., Flessas A., Ryan T.J., Brunner H.R., Faxon D.P., and Gavras I. Angiotensin II inhibition: Treatment of congestive cardiac failure in high-renin hypertension. The Journal of the American Medical Associations 238 (1977) 880-892
66. 2 receptor subtypes. Bioorganic & Medicinal Chemistry Letters 4 (1994) 2337-2342
67. Glinka T.W., de Laszlo S.E., Tran J., Chang R.S., Chen T.B., Lotti V.J., and Greenlee W.J. L-161638, a potent selective quinazolinone angiotensin II binding inhibitor. Bioorganic & Medicinal Chemistry Letters 4 (1994) 1479
68. 1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. Journal of Pharmacology and Experimental Therapeutics 298 1 (2001) 62-70
69. Gradman A.H., and Traub D. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Reviews in Cardiovascular Medicine 8 Suppl 2 (2007) S22-S30
70. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., and Bedigian M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
71. Grammatopoulos T.N., Jones S.M., Ahmadi F.A., Hoover B.R., Snell L.D., Skoch J., Jhaveri V.V., Poczobutt A.M., Weyhenmeyer J.A., and Zawada W.M. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Molecular Neurodegeneration 15 (2007) 2:1
72. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., Ostergren J., Pfeffer M.A., and Swedberg K. CHARM investigators and committees. effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 9386 (2003) 772-776
73. Gruden G., Thomas S., Burt D., Zhou W., Chusney G., Gnudi L., and Viberti G. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. Journal of the American Society of Nephrology 10 (1999) 730-737
74. Hall D., and Parsons S. Non-surmountable antagonism: a general drawback of pre-steady-state measurement?. Trends in Pharmacological Sciences 22 (2001) 63-65
75. Hauser W., Dendorfer A., Nguyen T., and Dominiak P. Effects of the AT1 antagonist HR 720 in comparison to losartan on stimulated sympathetic outflow, blood pressure, and heart rate in pithed spontaneously hypertensive rats. Kidney Blood Pressure Research 21 1 (1998) 29-35
76. Herbert J.M., Delisee C., Dol F., Schaeffer P., Cazaubon C., Nisato D., and Chatelain P. Effect of SR 47436, a novel angiotensin II AT 1 receptor antagonist, on human vascular smooth muscle cells in vitro. European Journal of Pharmacology 251 2-3 (1994) 143-150
77. 1 receptor antagonist. British Journal of Pharmacology 111 (1994) 137-144
78. 1 receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 272 (1995) 750-757
79. Horiuchi M., Akishita M., and Dzau V.J. Recent progress in angiotensin type 2 receptor research in the cardiovascular system. Hypertension 33 (1999) 613-621
80. Hropot M., Langer K.H., Wiemer G., Grotsch H., and Linz W. Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats. Naunyn-Schmiedeberg's Archives in Pharmacology 367 3 (2003) 312-317
81. Inada Y., Murakami M., Kaido K., and Nakao K. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension. Arzneim-Forsch/Drug Research 49 (1999) 13-21
82. Inada Y., Murakami M., Tazawa S., and Akahane M. KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive rats. Clinical Experimental Pharmacology & Physiology 27 4 (2000) 270-276
83. Inada Y., Tazawa S., Murakami M., and Akahane M. KRH-594, a new angiotensin AT1 receptor antagonist, prevents end-organ damage in stroke-prone spontaneously hypertensive/Izm rats. Clinical Experimental Pharmacology & Physiology 28 3 (2001) 206-211
84. Inada Y., Nakane T., and Chiba S. Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors. Fundamental Clinical Pharmacology 16 4 (2002) 317-323
85. Iwai M., Liu H.W., Chen R., Ide A., Okamoto S., Hata R., Sakanaka M., Shiuchi T., and Horiuchi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110 (2004) 843-848
86. Jandeleit-Dahm K. Dual ACE/NEP inhibitors - more than playing the ACE card. Journal of Human Hypertension 20 (2006) 478-481
87. Jin D., Song K., Oka Y., Takai S., Shiota N., and Miyazaki M. Pharmacological profiles of a novel non-peptide angiotensin II type 1 receptor antagonist HR 720 in vitro and in vivo. Japanese Journal of Pharmacology 75 (1997) 259-266
88. Johnston C.I., Hodsman P.G., Kohzuki M., Casley D.J., Fabris B., and Phillips P.A. Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists. American Journal of Medicine 87 (1989) 24S-28S
89. Juan G.P., María A.M.L., Teresa S.B., José I.B., and Rosa T.J. Clinical Profile of Eprosartan. Cardiovascular Drugs and Therapy 16 (2004) 1573-7241
90. Judd D.B., Cardwell K.S., Panchal T.A., Jack T.I., Pass M., Hubbard T., Dean A.W., Butt A.U., Hobson J.E., Heron N.M., Watson S.P., Currie G.S., Middlemiss D., Allen D.G., Aston N.M., Paton J.M.S., Drew G.M., Hilditch A., Gallacher D., Bayliss M.K., and Donnelly M.C. Benzofuran based non-peptide antagonists of angiotensin II related to GR 117289. Part IV; imidazopyridinylbenzofurans. Bioorganic & Medicinal Chemistry Letters 4 (1994) 725-728
91. Julius S., Weber M.A., Kjeldsen S.E., McInnes G.T., Zanchetti A., Brunner H.R., Laragh J., Schork M.A., Hua T.A., Amerena J., Balazovjech I., Cassel G., Herczeg B., Koylan N., Magometschnigg D., Majahalme S., Martinez F., Oigman W., Seabra Gomes R., and Zhu J.R. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 48 3 (2006) 385-391
92. Kaschina E., and Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Pressure 12 2 (2003) 70-88
93. Kawasaki H., Inaizumi K., Nakamura A., Hobara N., and Kurosaki Y. Chronic angiotensin II inhibition increases levels of calcitonin gene-related peptide mRNA of the dorsal root ganglia in spontaneously hypertensive rats. Hypertension Research 26 3 (2003) 257-263
94. Kitos T.E., Drobnies A., Ng M.N.P., Wen Y., and Cornell R.B. Contribution of lipid mediators to the regulation of phosphatidylcholine synthesis by angiotensin. Biochimica et Biophysisica Acta 1761 (2006) 261-271
95. Kleinert H.D., Baker W.R., and Stein H.H. Renin inhibitors. Advances in Pharmacology 22 (1991) 207-250
96. 2-specific angiotensin II receptor binding inhibitory activity. Bioorganic & Medicinal Chemistry Letters 4 (1994) 57-62
97. 1-selective angiotensin II receptor antagonist. Naunyn-Schmeideberg's Archives of Pharmacology 353 (1996) R69
98. Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. American Journal of Cardiology 87 (2001) 33C-36C
99. Konstam M.A., Neaton J.D., Poole-Wilson P.A., Pitt B., Segal R., Sharma D., Dasbach E.J., Carides G.W., Dickstein K., Riegger G., Camm A.J., Martinez F.A., Bradstreet D.C., Ikeda L.S., Santoro E.P., and ELITE II Investigators. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). American Heart Journal 150 1 (2005) 123-131
100. Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D., and Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American Journal of Hypertension 17 (2004) 103-111
101. Kowala M.C., Murugesan N., Tellew J., Carlson K., Monshizadegan H., Ryan C., Gu Z., Kane B., Fadnis L., Baska R.A., Beyer S., Arthur S., Dickinson K., Zhang D., Perrone M., Ferrer P., Giancarli M., Baumann J., Bird E., Panchal B., Yang Y., Trippodo N., Barrish J., and Macor J.E. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension. Journal of Pharmacology and Experimental Therapeutics 309 1 (2004) 275-284
102. Kramkowski K., Mogielnicki A., and Buczko W. The physiological significance of the alternative pathways of angiotensin II production. Journal of Physiology and Pharmacology 57 4 (2006) 529-539
103. Kruger B., Boger C., Stubanus M., Fischereder M., and Kramer B.K. The COOPERATE trial. Lancet 361 9362 (2003) 1054
104. Kurokawa K., Chan J.C., Cooper M.E., Keane W.F., Shahinfar S., and Zhang Z. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clinical and Experimental Nephrology 10 3 (2006) 193-200
105. Kurtz T.W., and Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. Journal of Hypertension 22 12 (2004) 2253-2261
106. Lee E.Y., Shim M.S., Kim M.J., Hong S.Y., Shin Y.G., and Chung C.H. Angiotensin II receptor blockerattenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Expert in Molecular Medicine 36 1 (2004) 65-70
107. Li X., Zhang H., Soledad-Conrad V., Zhuang J., and Uhal B.D. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. American Journal of Physiology-Lung Cellular and Molecular Physiology 284 3 (2003) L501-L507
108. Linz W., Heitsch H., Scholkens B.A., and Wiemer G. Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension 35 4 (2000) 908-913
109. Leung P.S. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. Diabetes Medicine 24 2 (2007) 110-116
110. Lew M.J., Ziogas J., and Christopoulos A. Dynamic mechanisms of non-classical antagonism by competitive AT1 receptor antagonists. Trends in Pharmacological Sciences 21 (2000) 376-381
111. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I., and Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 345 12 (2001) 851-860
112. 2-induced contractions in canine coronary arteries. Journal of Pharmacology and Experimental Therapeutics 281 (1997) 1065-1070
113. 2-induced vasoconstriction in canine coronary arteries and human platelet aggregation. Journal of Pharmacology and Experimental Therapeutics 292 1 (2000) 238-246
114. 2 receptor protects against cerebral ischemia induced neuronal injury. The FASEB Journal 19 (2005) 617-619
115. Link A., Lenz M., Legner D., Bohm M., and Nickenig G. Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes. Journal of Hypertension 24 9 (2006) 1891-1898
116. Luetscher J.A., Kraemer F.B., Wilson D.M., Schwartz H.C., and Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. The New England Journal of Medicine 312 (1985) 1412-1417
117. Maggioni A.P. Efficacy of Angiotensin receptor blockers in cardiovascular disease. Cardiovascular Drugs Therapy 20 4 (2006) 295-308
118. Maggioni A.P., and Fabbri G. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opinion in Pharmacotherapeutics 6 3 (2005) 507-512
119. Maggioni A.P., Latini R., Carson P.E., Singh S.N., Barlera S., Glazer R., Masson S., Cere E., Tognoni G., Cohn J.N., and Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal 149 3 (2005) 548-557
120. Massie B.M. 15 years, of heart-failure trials: what have we learned?. Lancet 352 I (1998) SI29-SI33
121. Mc Clellan K.J., and Balfour J.A. Eprosartan. Drugs 55 (1998) 713-720
122. McClean D.R., Ikram H., Garlick A.H., Richards A.M., Nicholls M.G., and Crozier I.G. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. Journal of American College of Cardiology 36 (2000) 479-486
123. McKelvie R.S., Yusuf S., Pericak D., Avezum A., Burns R.J., Probstfield J., Tsuyuki R.T., White M., Rouleau J., Latini R., Maggioni A., Young J., and Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 100 10 (1999) 1056-1064
124. 2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Molecular and Cellular Endocrinology 122 (1996) 59-67
125. Middlemiss D., Drew G.M., Ross B.C., Robertson M.J., Scopes D.I.C., Dowle M.D., Akers J., Cardwell K., Clark K.L., Coote S., Eldreel C.D., Hamblett J., Hilditch A., Hirst G.C., Jack T., Montana J., Panchal T.A., Paton J.M.S., Shah P., Stuart G., and Travers A. Bromobenzofurans: a new class of potent nonpeptide antagonists of angiotensin II. Bioorganic & Medicinal Chemistry Letters 1 (1991) 711-716
126. Miura S., Saku K., and Karnik S.S. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertension Research 26 12 (2003) 937-943
127. Miura S., Fujino M., and Saku K. Angiotensin II Receptor Blocker as an Inverse Agonist: A Current Perspective. Current Hypertension Reviews 1 (2005) 115-121
128. Miura S.-I., Fujino M., Hanzawa H., Kiya Y., Imaizumi S., Matsuo Y., Tomita S., Uehara Y., Karnik S.S., Yanagisawa H., Koike H., Komuro I., and Saku K. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. Journal of Biological Chemistry 281 28 (2006) 19288-19295
129. Miyamoto H., Ito K., Wakabayashi S., Suzaka H., Matsuo H., Iga T., and Sawada Y. Comparative study of effects of angiotensin II receptor antagonist, KD3-671, and angiotensin converting enzyme inhibitor, enalaprilat, on cough reflex in guinea pig. European Journal of Drug Metabolism and Pharmacokinetics 26 1-2 (2001) 47-52
130. Miyauchi N., and Nakamura Y. Antiproteinuric effect of an angiotensin II receptor antagonist in membranous nephropathy. Nephron 88 (2001) 183-184
131. Miyazaki M., Sakonjo H., and Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in cynomolgus monkeys fed a high-cholesterol diet. British Journal of Pharmacology 128 3 (1999) 523-529
132. Mizuno M., Sada T., Ikeda M., Fukuda N., Miyamoto M., Yanasigawa H., and Koike H. Pharmacology of CS-866, a novel non-peptide angiotensin II receptor antagonist. European Journal of Pharmacology 285 (1995) 181-188
133. Mochizuki S., Sato T., Furuta K., Hase K., Ohkura Y., Fukai C., Kosakai K., Wakabayashi S., and Tomiyama A. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. Journal of Cardiovascular Pharmacology 25 (1995) 22-29
134. Murugesan N., Tellew J.E., Gu Z., Kunst B.L., Fadnis L., Cornelius L.A., Baska R.A., Yang Y., Beyer S.M., Monshizadegan H., Dickinson K.E., Panchal B., Valentine M.T., Chong S., Morrison R.A., Carlson K.E., Powell J.R., Moreland S., Barrish J.C., Kowala M.C., and Macor J.E. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. Journal of Medicinal Chemistry 45 (2002) 3829-3835
135. Murugesan N., Gu Z., Fadnis L., Tellew J.E., Baska R.A., Yang Y., Beyer
136. Nagamatsu T., Oka T., Nagao T., and Suzuki Y. Effects of KD3-671, an angiotensin II type 1 receptor antagonist, on anti-thy-1 nephritis in rats. Biology & Pharmacy Bulletin 26 6 (2003) 808-812
137. Nakao N., Seno H., Kasuga H., Toriyama T., Kawahara H., and Fukagawa M. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABPsubstudy. American Journal of Nephrology 24 5 (2004) 543-548
138. Neutel J.M. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. American Journal of Cardiology 87 (2001) 37C-43C
139. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Advances in Therapy 15 (1998) 206-217
140. Nishikawa K., Inada Y., Shibouta Y., Wada T., Ojima M., Kubo K., and Naka T. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116. Blood Pressure 5 (1994) 7-14
141. Noda M., Shibouta Y., Inada Y., Ojima M., Wada T., Sanada T., Kubo K., Kohara Y., Naka T., and Nishikawa K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochemical Pharmacology 46 (1993) 311-318
142. Norwood D., Branch III E., Smith B., and Honeywell M. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast 27 12 (2002) 611-618
143. Nussberger J., Waeber B., and Brunner H.R. Clinical pharmacology of ACE inhibition. Cardiology 76 2 (1989) 11-22
144. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., and Agostini A. Plasma bradykinin in angio-oedema. Lancet 351 (1998) 1693-1697
145. Oka-Akagi T., Fujimori A., Shibasaki M., Matsuda-Satoh Y., Inagaki O., and Yanagisawa I. Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in rats. Biology & Pharmacy Bulletin 25 7 (2002) 857-860
146. Oparil S. Additive blood pressure reduction with novel direct renin inhibitor plus valsartan. American College of Cardiology 56th Annual Scientific Session, 24-27 March (2007)
147. Opie L.H., and Sack M.N. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circulation Research 88 (2001) 654-658
148. 1-selective nonpeptidic angiotensin II (AII) receptor antagonist. The FASEB Journal 8 (1994) A5
149. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 9386 (2003) 759-766
150. Pitt B., Segal R., and Martinez F.A. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In the Elderly study, ELITE). Lancet 349 (1997) 747-752
151. Pitt B., Poole-Wilson P.A., Segal R., Martinez F., Dickstein K., Camm A., Konstam M., Riegger G., Klinger G., and Neaton N. Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 355 9215 (2000) 1582-1587
152. Pool J.L., Schmieder R.E., Azizi M., Aldigier J.C., Januszewicz A., Zidek W., Chiang Y., and Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension 20 1 (2007) 11-20
153. Privratsky J.R., Wold L.E., Sowers J.R., Quinn M.T., and Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42 2 (2003) 206-212
154. Puchler K., Nussberger J., Laeis P., Witte P.U., and Brunner H.R. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. Journal of Hypertension 15 (1997) 1809-1812
155. Pu Q., Amiri F., Gannon P., and Schiffrin E.L. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. Journal of Hypertension 23 (2005) 401-409
156. Rahuel J., Rasetti V., Maibaum J., Rueger H., Goschke R., Cohen N.C., Stutz S., Cumin F., Fuhrer W., Wood J.M., and Grutter M.G. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chemical Bioogy l 7 (2000) 493-504
157. Rastegar M.A., Marchini F., Morazzoni G., Vegh A., Papp J.G., and Parratt J.R. The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. British Journal of Pharmacology 129 4 (2000) 671-680
158. Rhaleb N.E., Rouissi N., Nantel F., D'Orleans-Juste P., and Regoli D. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 17 4 (1991) 480-484
159. Ries U.J., Mihm G., Narr B., Hasselbach K.M., Wittneben H., Entzeroth M., Van Meel J.C.A., Wienen W., and Hauel N.H. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships. Journal of Medicinal Chemistry 36 (1993) 4040-4051
160. Robertson M.J., Dougall I.G., Harper D., McKechnie K.C., and Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends in Pharmacological Sciences 15 10 (1994) 364-369
161. Rump L.C. Secondary rise of albuminuria under AT1-receptor blockade-what is the potential role of aldosterone escape?. Nephrology Dialysis Transplantation 22 1 (2007) 5-8
162. Ruster C., and Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. Journal of American Society of Nephrology 17 11 (2006) 2985-2991
163. Samanen J.M., Peishoff C.E., Keenan R.M., and Weinstock J. Refinement of a molecular model of angiotensin II (AII) employed in the discovery of potent nonpeptide antagonists. Bioorganic & Medicinal Chemistry Letters 3 (1993) 909-914
164. Sasaki K., Yamano Y., Bardhan S., Iwai N., Murray J.J., Hasegawa M., Matsuda Y., and Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature (London) 351 (1991) 230-232
165. Schmieder R.E. Aliskiren: a clinical profile. Journal of Renin Angiotensin Aldosterone System 7 Suppl 2 (2006) S16-S20
166. Schwocho L.R., and Masonson H.N. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. The Journal of Clinical Pharmacology 41 (2001) 515-527
167. Sealey J.E., and Laragh J.H. Aliskiren, the first renin inhibitor for treating hypertension: reactive Renin secretion may limit its effectiveness. American Journal of Hypertension 20 5 (2007) 587-597
168. 2) receptor mRNA in the rat. Kidney International 47 (1995) 1095-1100
169. Shibouta Y., Inada Y., Ojima M., Wada T., Noda M., Sanada T., Kubo K., and Nishikawa K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist [(2′-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (□)-1-(cyclohexyloxy carbonyloxy)-ethyl-2-ethoxy-1-[2′-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl]-1H-benzimidazole-7-carboxylate (TCV 116). Journal of Pharmacology and Experimental Therapeutics 266 (1993) 114-120
170. Silver R.B., Reid A.C., Mackins C.J., Askwith T., Schaefer U., Herzlinger D., and Levi R. Mast cells: a unique source of renin. Proceedings of the National Academy of Sciences of the United States of America 101 37 (2004) 13607-13612
171. Smeby R.R., and Fermandjian S. Conformation of angiotensin II. In: Weinstein B. (Ed). Chemistry and Biochemistry of Amino Acids, Peptides and Proteins (1978), Marcel Dekker, Inc, New York 117
172. Smith R.D., and Timmermans P.B.M.W.M. Human angiotensin receptor subtypes. Current Opinion in Nephrology and Hypertension 3 (1994) 112-122
173. Staessen J.A., Li Y., and Richart T. Oral renin inhibitors. Lancet 368 9545 (2006) 1449-1456
174. Stasch J.-P., Knorr A., Hirth-Dietrich C., Kramer T., Hubsch W., Dressel J., Fey P., Beuck M., Sander E., Frobel K., and Kazda S. Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats, and stroke-prone spontaneously hypertensive rats. Arzneim-Forsch/Drug Research 47 (1997) 1016-1023
175. 2 receptor-a matter of love and hate. Peptides 26 (2005) 1401-1409
176. Stier Jr. C.T., Rocha R., and Chander P.N. Effect of aldosterone and MR blockade on the brain and the kidney. Heart Failure Reviews 10 1 (2005) 53-62
177. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. The Journal of Clinical Investigation 95 (1995) 3954-3962
178. Streeten D.H.P., Anderson Jr. G.H., Freiberg J.M., and Dalakos T.G. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension. New England Journal of Medicine 292 (1975) 657-662
179. Sulpizio A.C., Pullen M.A., Edwards R.M., and Brooks D.P. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. Journal of Pharmacology and Experimental Therapeutics 309 (2004) 1141-1147
180. Swedberg K. Exploring new treatment strategies in heart failure. Blood Pressure 1 (2000) 44-48
181. Sweet C.S., and Nelson E.B. How well have animal studies with losartan predicted responses in humans?. Journal of Hypertension 11 (1993) S63-S67
182. Tallant E.A., Diz D.I., and Ferrario C.M. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34 (1999) 950-957
183. 1-receptor antagonist, in renal hypertensive dogs. Journal of Cardiovascular Pharmacology 32 (1998) 834-844
184. 1 receptor antagonist, attenuates vascular but not cardiac responses to sympathetic nerve stimulation in pithed rats. Journal of Cardiovascular Pharmacology 37 (2001) 427-436
185. Tamura K., Okuhira M., Amano H., Inokuma K.-I., Hirata T., Mikoshiba I., and Hashimoto K. Pharmacological profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist. Journal of Cardiovascular Pharmacology 30 (1997) 607-615
186. Tanabe N., Ueno A., and Tsujimoto G. Angiotensin II receptors in the rat urinary bladder smooth muscle: type 1 subtype receptors mediate contractile responses. Journal of Urology 150 3 (1993) 1056-1059
187. Tanahashi N. Stroke and renin-angiotensin system. Nippon Rinsho 64 6 (2006) 1191-1199
188. Tellew J.E., Baska R.A., Beyer S.M., Carlson K.E., Cornelius L.A., Fadnis L., Gu Z., Kunst B.L., Kowala M.C., Monshizadegan H., Murugesan N., Ryan C.S., Valentine M.T., Yang Y., and Macor J.E. Discovery of 4′-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists. Bioorganic & Medicinal Chemistry Letters 13 6 (2003) 1093-1096
189. Thomas A.P., Allot C.P., Gibson K.H., Major J.S., Masek B.B., Oldhman A.A., Rateliffe A.H., Roberts D.A., Russel S.T., and Thomason D.A. New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties and structure activity relationships of 2-alkylbenzimidazole derivatives. Journal of Medicinal Chemistry 35 (1992) 877-885
190. Thomas G.P., Ferrier G.R., and Howlett S.E. Losartan exerts antiarryhthmic activity independent of angiotensin II receptor blockade in simulated ventricular ischaemia and reperfusion. Journal of Pharmacology and Experimental Therapeutics 278 (1996) 1090-1097
191. Timmermans P.B.M.W.M., Carini D.J., Chiu A.T., Duncia J.V., Price Jr. W.A., Wells G.J., Wong P.C., Wexler R.R., and Johnson A.L. Angiotensin II receptor antagonists: From discovery to antihypertensive drugs. Hypertension 18 III (1991) III136-III142
192. Timmermans P.B.M.W.M., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A.M., and Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacological Reviews 45 (1993) 205-251
193. Tokioka T., Shibasaki M., Inagaki O., Okazaki T., Yanasigawa I., Sato N., and Takenaka T. Antihypertensive effects of YM 358, a novel angiotensin II receptor antagonist, in rats with one-kidney, one clip hypertension. Japanese Journal of Pharmacology 64 1 (1994) 83P
194. Tokioka T., Shibasaki M., Fujimori A., Matsuda-Satoh Y., Uchida W., Inagaki O., and Yanagisawa I. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biology & Pharmacy Bulletin 23 2 (2000) 174-181
195. Tokioka-Akagi T., Fujimori A., Shibasaki M., Inagaki O., and Yanagisawa I. Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload. Japanese Journal of Pharmacology 86 1 (2001) 79-85
196. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Archives of Internal Medicine 161 (2001) 1492-1499
197. Tox U., and Steffen H.M. Impact of inhibitors of the renin-angiotensin-aldosterone system on liver fibrosis and portal hypertension. Current Medicinal Chemistry 13 30 (2006) 3649-3661
198. Trenkwalder P. Reducing cardiovascular morbidity and mortality in the elderly. Blood Pressure 1 (2000) 40-43
199. Turker R.K., Page I.H., and Bumpus F.M. Antagonists of angiotensin II. In: Page, and Bumpus (Eds). Angiotensin (1974), Springer Verlag, New York 162-169
200. Ueda S., Masumori-Maemoto S., Ashino K., Nagahara T., Gotoh E., Umemura S., and Ishii M. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35 (2000) 998-1001
201. Uemura H., Ishiguro H., and Kubota Y. Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Reviews in Medicinal Chemistry 6 7 (2006) 835-844
202. Uhlenius N., Miettinen A., Vuolteenaho O., and Tikkanen I. Renoprotective mechanisms of angiotensin II antagonism in sexperimental chronic renal failure. Kidney Blood Pressure Research 25 2 (2002) 71-79
203. 2 site. Journal of Medicinal Chemistry 36 (1993) 3985-3992
204. Van Epps H.L. Harry Goldblatt and the discovery of renin. Journal of Experimental Medicine 201 9 (2005) 1351
205. Vinson G.P., Ho M.M., and Puddefoot J.R. The distribution of angiotensin II type 1 receptors, and the tissue renin-angiotensin systems. Molecular Medicine Today 1 (1995) 35-39
206. Wang J.M., Tan J., and Leenen F.H. Central nervous system blockade by peripheral administration of AT1 receptor blockers. Journal of Cardiovascular Pharmacology 41 4 (2003) 593-599
207. Weinstock J., Keenan R.M., Samanen J., Hempel J., Finkelstein J.A., Franz R.G., Gaitanopoulos D.E., Girard G.R., Gleason J.G., Hill D.T., Morgan T.M., Peishoff C.E., Aiyar N., Brooks D.P., Frederickson T.A., Ohlstein E.H., Ruffolo R.R., Stack E.J., Sulpizio A.C., Weidley E.F., and Edwards R.M. 1-(Carboxybenzyl)-imidazole-5-acrylic acids: Potent and selective angiotensin II receptor antagonists. Journal of Medicinal Chemistry 34 (1991) 1514-1517
208. White H.D., Aylward P.E., Huang Z., Dalby A.J., Weaver W.D., Barvik S., Marin-Neto J.A., Murin J., Nordlander R.O., van Gilst W.H., Zannad F., McMurray J.J., Califf R.M., Pfeffer M.A., and VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 112 22 (2005) 3391-3399
209. Whitebread S., Mele M., Kamber B., and de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochemical and Biophysical Research Communications 163 (1989) 284-291
210. 1 receptor blockers in hypertension and heart failure: Clinical experience and future directions. European Heart Journal 20 (1999) 997-1008
211. Wong P.C., Price Jr. W.A., Chiu A.T., Carini D.J., Duncia J.V., Johnson A.L., Wexler R.R., and Timmermans P.B.M.W.M. Nonpeptide angiotensin II receptor antagonists: Studies with EXP 9270 and DuP 753. Hypertension 15 (1990) 823-834
212. Wong P.C., Price Jr. W.A., Chiu A.T., Duncia J.V., Carini D.J., Wexler R.R., Johnson A.L., and Timmermans P.B.M.W.M. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonist: X. Hypertension 15 (1990) 459-468
213. Wong P.C., Price Jr. W.A., Chiu A.T., Duncia J.V., Carini D.J., Wexler R.R., Johnson A.L., and Timmermans P.B.M.W.M. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. Journal of Pharmacology and Experimental Therapeutics 252 (1990) 726-732
214. Wong P.C., Hart S.D., Zaspel A., Chiu A.T., Smith R.D., and Timmermans P.B.M.W.M. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD 123177 (AII-2). Journal of Pharmacology and Experimental Therapeutics 255 (1990) 584-592
215. Wong P.C., Price Jr. W.A., Chiu A.T., Duncia J.V., Carini D.J., Wexler R.R., Johnson A.L., and Timmermans P.B.M.W.M. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 3174, an active metabolite of DuP 753-An orally active antihypertensive agent. Journal of Pharmacology and Experimental Therapeutics 255 (1990) 211-217
216. 1 receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 259 (1991) 861-870
217. 2 receptor subtypes. European Journal of Pharmacology 260 (1994) 261-264
218. 2 receptor subtype. Journal of Cardiovascular Pharmacology 26 (1995) 354-362
219. Wood J.M., Maibaum J., Rahuel J., Grutter M.G., Cohen N.C., Rasetti V., Ruger H., Goschke R., Stutz S., Fuhrer W., Schilling W., Rigollier P., Yamaguchi Y., Cumin F., Baum H.P., Schnell C.R., Herold P., Mah R., Jensen C., O'Brien E., Stanton A., and Bedigian M.P. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochemical and Biophysical Research Communications 308 (2003) 698-705
220. Wood H.M., and Ernst M.E. Renin-angiotensin system mediators and Raynaud's phenomenon. Annals in Pharmacotherapeutics 40 11 (2006) 1998-2002
221. Wu L., Iwai M., Nakagami H., Li Z., Chen R., Suzuki J., Akishita M., de Gasparo M., and Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104 (2001) 2716-2721
222. 2-selective angiotensin II receptor antagonists. Bioorganic & Medicinal Chemistry Letters 3 (1993) 2023-2028
223. 2 receptor subtypes. Bioorganic & Medicinal Chemistry Letters 4 (1994) 17-22
224. Xia Q.G., Chung O., Spitznagel H., Illner S., Janichen G., Rossius B., Gohlke P., and Unger T. Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure. Cardiovascular Research 49 1 (2001) 110-117
225. Yamagishi S., and Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Medical Hypotheses 64 3 (2005) 476-478
226. Yamagishi S., Takenaka K., and Inoue H. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Medical Hypotheses 66 1 (2006) 118-120
227. 1-receptor antagonist, in stroke-prone spontaneously hypertensive rats. Japanese Journal of Pharmacology 73 (1997) 83-91
228. Yanagisawa T., Ueyama N., Kawai T., Sonegawa M., Baba H., Mochizuki S., Kozakai K., and Tomiyama T. 4,5,6,7-Tetrahydro-8-oxo-cycloheptimidazoles: a new class of potent nonpeptide angiotensin II receptor antagonist. Bioorganic & Medicinal Chemistry Letters 3 (1993) 1559-1564
229. Yoneyama M., Sugiyama A., Yoshida H., Satoh Y., and Hashimoto K. Cardiovascular effects of L-158,809, a new angiotensin type 1 receptor antagonist, assessed using the halothane-anesthetized in vivo canine model. Japanese Journal of Pharmacology 89 2 (2002) 192-196
230. Yoshida M., Naito Y., Urano T., Takada A., and Takada Y. L-158,809 and (D-Ala(7))-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells. Thrombus Research 105 6 (2002) 531-536
231. Yun C.H., Lee H., Rho J.K., Jeong H.G., and Guengerich F.P. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P450 3A(4) in formation of the active metabolite EXP 3174. Drug Metabolism and Disposition 23 (1995) 285-289
232. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. American Journal of Cardiology 89 2A (2002) 18A-25A
233. Yusuf S., Ostergren J.B., Gerstein H.C., Pfeffer M.A., Swedberg K., Granger C.B., Olofsson B., Probstfield J., McMurray J.V., and Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112 1 (2005) 48-53
234. Zanchetti A., and Elmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. Blood Pressure 15 2 (2006) 71-79
235. Zanchetti A., Julius S., Kjeldsen S., McInnes G.T., Hua T., Weber M.A., Laragh J.H., Plat F., Battegay E., Calvo-Vargas C., Cieslinski A., Degaute J.P., Holwerda N.J., Kobalava J., Pedersen O.L., Rudyatmoko F.P., Siamopoulos K.C., and Storset O. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. Journal of Hypertension 24 11 (2006) 2163-2168
236. Zhang J., Entzeroth M., Wienen W., and Van Meel J.C. Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. European Journal of Pharmacology 218 1 (1992) 35-41
237. Zhang J., Van Meel J.C.A., and Van Zwieten P.A. Antihypertensive activity of the novel, nonpeptide angiotensin II receptor antagonists BIBS 39 and BIBS 222 in conscious renal hypertensive rats. Pharmacology 46 (1993) 241-247
238. Zhang H., Zhang D., Li W., Yao M., Darienzo C., Li Y.X., Ewing W.R., Gu Z., Zhu Y., Murugesan N., Shyu W.C., and Humphreys W.G. Reduction of site-specific cyp3a-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys. Drug Metabolism and Disposition 35 5 (2007) 795-805